Clinical Trial Update: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib (XL184) in combination with nivolumab and ipilimumab for poorly differentiated neuroendocrine tumors; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma
• Neuroendocrine Neoplasm
• Small Cell Neuroendocrine Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-12